Number To Know…56
56% is the stake that Theraclion has in a Chinese joint venture it has recently set up to sell its Echopulse high-intensity focused ultrasound system.
French echotherapy specialist Theraclion SAS will take a 56% stake in a China-based joint venture it is setting up with one of its own shareholders, Chinese healthcare company Inner Mongolia Furui Medical Science Co. Ltd. Theraclion China Co, Ltd., to be based in the southern city of Shenzhen, will sell the Theraclion’s Echopulse system, designed as a noninvasive alternative to surgery by excising benign thyroid nodules and removing breast fibroadenoma using high-intensity focused ultrasound (HIFU). According to Theraclion, China is the “biggest addressable market” for the company’s products, as it represents over 50% of surgeries for benign thyroid nodules and breast fibroadenoma. The JV partnership, announced in April, was one of the deals recorded by Strategic Transactions and listed in Medtech Insight‘s bi-monthly Pacts In Medtech series.